--- title: "China Pharma Holdings (CPHI) news: going concern and offering" url: "https://aibio.space/companies/china-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CPHI going concern and offering news: China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss." --- CPHI China Pharma Holdings, Inc. AMEX · China # China Pharma Holdings (CPHI) news CPHI going concern and offering news Financings · 2026-07-22 ## [China Pharma prices $5 million registered direct offering](https://aibio.space/news/china-pharma-prices-5-million-registered-direct-offering/) China Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent. ## Latest China Pharma Holdings news 1. 2026-04-01 Distress [China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss](https://aibio.space/news/china-pharma-holdings-files-nt-10-k-late-annual-report-estimates-3-19/) China Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before. 2. 2026-03-03 Financings [China Pharma to issue 12,600,000 shares for $6.93 million patent transfer](https://aibio.space/news/china-pharma-issue-12-600-000-shares-6-93-million-patent-transfer/) China Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report. ## China Pharma Holdings at a glance - **Ticker**: CPHI - **Listing**: AMEX - **Country**: China - **Cash, Jun 30, 2026**: $304,874 ### Related companies - [Hightide Therapeutics](https://aibio.space/companies/hightide-therapeutics/) HKEX: 2511 - [Keymed Biosciences](https://aibio.space/companies/keymed-biosciences/) HKEX: 2162 - [Hua Medicine](https://aibio.space/companies/hua-medicine/) HKEX: 2552 - [Yabao Pharmaceutical Group Co.](https://aibio.space/companies/yabao-pharmaceutical/) SSE: 600351 - [Zhejiang Wolwo Bio-Pharmaceutical Co.](https://aibio.space/companies/zhejiang-wolwo-bio-pharmaceutical/) SZSE: 300357 - [Hainan Haiyao Co.](https://aibio.space/companies/hainan-haiyao/) SZSE: 000566 - [Aurisco Pharmaceutical Co.](https://aibio.space/companies/aurisco-pharmaceutical/) SSE: 605116 - [Beijing Beilu Pharmaceutical Co.](https://aibio.space/companies/beijing-beilu-pharmaceutical/) SZSE: 300016 ### Also on AMEX - [OS Therapies](https://aibio.space/companies/os-therapies/) OSTX - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) CLDI ## What China Pharma Holdings does China Pharma Holdings, Inc. is a Nevada holding company whose operations are conducted through its wholly owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. (Helpson) and Helpson's subsidiaries in China. Through Helpson, the company develops, manufactures and markets pharmaceutical products for a variety of high-incidence and high-mortality diseases in the People's Republic of China. Helpson makes dry powder injectables, liquid injectables, tablets, capsules and cephalosporin oral solutions. Most of its products are sold on a prescription basis, and all have been approved for at least one therapeutic indication by the National Medical Products Administration. As of December 31, 2025, the company held rights to manufacture 19 pharmaceutical products in three categories: basic generic drugs, first-to-market generic drugs, and modern Traditional Chinese Medicines. Helpson operates two production facilities in Haikou, Hainan Province, and sells directly to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistic companies. | Product or program | What it is | Stage | |---|---|---| | Basic generic drugs | Common drugs with very large market demand in the PRC | Approved for at least one indication by the NMPA | | First-to-market generic drugs | Generic drugs that are new to the PRC marketplace | Approved for at least one indication by the NMPA | | Modern Traditional Chinese Medicines | Plant-based medicinal compounds widely used in the PRC | Approved for at least one indication by the NMPA | | Injectables, tablets, capsules and oral solutions | Dry powder and liquid injectables, tablets, capsules and cephalosporin oral solutions | Approved for at least one indication by the NMPA | Summarised from the company's [10-K filed Apr 1, 2026](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm). ## China Pharma Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$4.1 million](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | | Research and development | [$280,901](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | [$283,942](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | | Net income (loss) | [-$3.2 million](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | | Cash from operations | [$148,261](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | [-$406,063](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | | Cash and equivalents | [$345,112](https://www.sec.gov/Archives/edgar/data/1106644/000121390026090173/) | [$626,879](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $304,874. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about China Pharma Holdings Has China Pharma Holdings issued a going-concern warning? Our latest story on this, dated Apr 1, 2026: "China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/china-pharma-holdings-files-nt-10-k-late-annual-report-estimates-3-19/). Has China Pharma Holdings raised money recently? Our latest story on this, dated Jul 22, 2026: "China Pharma prices $5 million registered direct offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/china-pharma-prices-5-million-registered-direct-offering/). What is the ticker symbol of China Pharma Holdings? China Pharma Holdings, Inc. trades under the ticker CPHI on AMEX. Where is China Pharma Holdings listed? China Pharma Holdings, Inc. is listed on AMEX. What is the SEC CIK of China Pharma Holdings? The SEC Central Index Key (CIK) for China Pharma Holdings, Inc. is 1106644. Its filings are on SEC EDGAR. How many shares does China Pharma Holdings have outstanding? 43,022,002 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is China Pharma Holdings listed under? Our directory records China Pharma Holdings, Inc. under China. What does China Pharma Holdings do? Our directory classifies China Pharma Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of China Pharma Holdings? The ISIN recorded for China Pharma Holdings, Inc. is US16941T4013. Does aibio.space cover China Pharma Holdings? aibio.space lists China Pharma Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is China Pharma Holdings incorporated? SEC records list its state or country of incorporation as DE. What does China Pharma Holdings develop? China Pharma Holdings, Inc. is a Nevada holding company whose operations are conducted through its wholly owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. (Helpson) and Helpson's subsidiaries in China. Through Helpson, the company develops, manufactures and markets pharmaceutical products for a variety of high-incidence and high-mortality diseases in the People's Republic of China. What is Basic generic drugs from China Pharma Holdings? Basic generic drugs: Common drugs with very large market demand in the PRC Stage: Approved for at least one indication by the NMPA. What is First-to-market generic drugs from China Pharma Holdings? First-to-market generic drugs: Generic drugs that are new to the PRC marketplace Stage: Approved for at least one indication by the NMPA. What was China Pharma Holdings's revenue last year? $4.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: China Pharma Holdings Members talk about China Pharma Holdings (CPHI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at China Pharma Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026114445/ea0310270-pre14a_chinapharma.htm) 2. 2026-07-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026080475/ea029892101ex99-1.htm) 3. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038495/ea0284590-nt10k_china.htm) 4. 2026-03-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026023022/ea0279672-8k_china.htm) 5. 2026-02-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026014338/ea0276369-8k_china.htm) 6. 2026-01-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390026001785/ea0271960-8k_chinapharm.htm) 7. 2025-12-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390025125299/ea0270909-8k_chinapharm.htm) 8. 2025-12-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390025120129/ea026901601-8k_chinapharma.htm) 9. 2025-11-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390025110882/ea0265803-def14a_chinapharma.htm) 10. 2025-11-04 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390025106092/ea0263708-pre14a_chinapharma.htm) 11. 2025-04-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390025029000/ea023720801ex99-1_china.htm) 12. 2024-12-26 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390024112658/ea022580301-8k_chinapharma.htm) 13. 2024-12-26 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390024112685/ea0226033-8k_china.htm) 14. 2024-11-12 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390024096780/ea0220766-def14a_chinapharma.htm) 15. 2024-11-01 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1106644/000121390024093490/ea0219517-pre14a_chinapharma.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:CPHI on TradingView](https://www.tradingview.com/symbols/AMEX-CPHI/). ## SEC filings and registration - **SEC name**: China Pharma Holdings, Inc. - **CIK**: 1106644 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CPHI (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2ND FLOOR, NO. 17, JINPAN ROAD, HAINAN PROVINCE, China, 570216 - **Phone**: 8689866811730 - **Shares outstanding**: 43,022,002 as of 2026-08-11 (10-Q filed 2026-08-14) - **Former names**: TS ELECTRONICS INC; SOFTSTONE INC; SOFTSTONE INC /DE/ ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1106644/000121390026090173/ea0301830-10q_china.htm) filed 2026-08-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1106644/000121390026080581/ea0298951-424b5_china.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1106644/000121390026080475/ea0298921-8k_china.htm) filed 2026-07-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1106644/000121390026057705/ea0290433-10q_china.htm) filed 2026-05-15 - [10-K](https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm) filed 2026-04-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1106644/000121390026023022/ea0279672-8k_china.htm) filed 2026-03-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1106644/000121390026014338/ea0276369-8k_china.htm) filed 2026-02-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1106644/000121390026001785/ea0271960-8k_chinapharm.htm) filed 2026-01-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001106644), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details China Pharma Holdings, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker CPHI, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: China Pharma Holdings, Inc. - **Ticker**: CPHI - **Listing**: AMEX - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: US16941T4013 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-CPHI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/china-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "China Pharma Holdings (CPHI) news: going concern and offering", 2026-10-31, https://aibio.space/companies/china-pharma/